Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New ECCO studies highlight promising potential of cancer immunotherapy

03.11.2005


New research findings showcased at the 13th European Cancer Conference (ECCO) have highlighted the important therapeutic potential of immunotherapy in the treatment of a number of different cancers e.g. for treatment of renal and skin cancers.



Renal cancer is the 6th leading cause of cancer death with a survival rate of 11% for stage-IV disease. More than a million skin cancer cases occur each year globally, with a 5-year survival rate of 7 to 9% and a 10-year survival rate of 3 to 6% for stage IV melanoma. These cancers are associated with significant mortality for which survival statistics have remained essentially unchanged for several decades. Past studies have indicated vaccination as a route to boosting anti-tumour T-cell reponses to help kill malignant cells. US investigator Dr Arkadiusz Dudek, from the University of Minnesota, and his team have developed a new method of vaccine-induced augmentation of tumour specific cytotoxic T-lymphocyte responses with the use of latex or silica beads.

The new large multivalent immunogen (LMI) was trialed in 61 patients with renal cancer or malignant melanoma with positive results.


In renal cancer patients, the LMI vaccine was found to prolong time to disease progression to 12.2 months. A significant increase when compared to the standard therapy of renal cancer (high dose interleukin-2) which produced a median progression-free survival of 3.1 months1. Using indicators of median overall survival, patients treated with high dose interleukin-2 survived 17.5 months1 and those treated with the LMI vaccine survived longer than 17.04 months and at current follow up, more than 19 months.

“Our study findings offer hope for patients with metastastic renal cell carcinoma, as this therapy stabilises and controls disease for an average of one year. For patients with metastastic malignant melanoma a large multivalent immunogen vaccine strategy needs to be optimised in order to obtain reproducible results. We hope that by utilising an allogeneic (using human donor cells/tissue) strategy we will observe more frequent and longer lasting responses. This vaccine strategy has no toxicities and treatment is convenient for patients as the vaccine is administered only once a month. In contrast, standard therapeutic strategy using high dose interleukin-2 is very toxic and limited only to selected patients with good performance status, and no cardiac or pulmonary co-morbidities,” noted Dr Dudek.

Another immunotherapeutic approach which seeks to boost the responses of effector CD8+ T-cells are DEX vaccines; Dendritic cell derived-EXosomes. In results presented at ECCO, the DEX vaccine, in combination with the alkylating agent cyclophosphamide (CTX), was found to produce antitumour effects superior to that obtained with either the peptide Gp100 plus CTX, or the best DEX vaccination approach currently available in a mouse model of melanoma.

In this new immunotherapeutic approach, CTX acts synergistically with DEX to abolish the function of Treg cells – cells induced by the tumour which suppress the CD8+ responses evoked by DEX. By abrogating the suppressive effect of Treg, CTX maximises the curative effects of DEX vaccination. The success of this combination approach suggests that future therapeutic vaccines aimed at boosting tumour-primed effector T-cells may benefit from procedures that minimise the pro-tumour effects of Treg cells.

About Renal Cancer

Renal cancer is defined as malignancy of the kidney, the organ that is primarily responsible for the removal of metabolic waste products from the body. In 2004, there were just under 40,000 incidents of renal cancer and 22,000 deaths across the EU.

About Immunotherapy

Immunotherapy is the treatment to stimulate or restore the ability of the immune (defense) system to fight infection and disease.

Kirsten Mason | alfa
Further information:
http://www.fecs.be/emc.asp?pageId=10&Type=P

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>